Orexigen Therapeutics — Corporate Update (January 2018)
17 slides from Orexigen Therapeutics's corporate update, Jan 19, 2018
Slide 1: Progress Report January 2018
Progress Report I January 2018 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its Contrave® product. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and sim
Slide 3: Contrave indication and boxed warning
Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio
Slide 4: 48% Higher Prescription Volume 4Q vs. 4Q
48% Higher Prescription Volume 4Q 17 vs. 4Q 16 TRx Growth (%) +23% Growth 2017 vs. 2016 Source: IQVIA NPA, partner provided fulfillment reports Contrave Channels include: Traditional + Home Delivery + Telemedicine
Slide 5: Projected TRx Volume: Contrave TRxs
Projected TRx Volume: Contrave® TRxs 2016 2017 2018 Source: IQVIA NPA, partner provided fulfillment reports, Orexigen estimates Jan. 2018-Dec. 2018 1,315K 1,100K 691K 848K 4Q16 vs. 4Q17: +48% +30% +55% Contrave Channels include: Traditional + Home Delivery + Telemedicine
Slide 6: Key Actions for 2018
Key Actions for 2018 Weight Loss Campaign Physician Promotion Increase focus on 7K high ROI prescribers Evolve to new engagement model via business to business/account management Evolve to include patient education/outreach Highly efficient digital speaker programs Focus messaging on discussing crav
Slide 7: TRx volume higher with DTC campaigns
Main Season No DTC Fall Season No DTC Main Season With DTC Fall Season With DTC TRx volume is >30% higher vs. same period last year Source: IQVIA NPA Weekly, Week Ending 1/12/18, partner reported fulfillment reports Note: Digital and Print Ads are still active after 2nd week of May Fall Campaign sta
Slide 8: Improving digital engagement vs. prior years
In addition to improved TRx performance, both the quantity and quality of digital engagements is improving vs. prior years Total Market Share Current Wk. vs. Prior Season CA/TX Fulfillments CA/TX Telemedicine/Home Delivery Fulfillments Current Wk. vs. Prior Season Total Market Share Avg. Session Dur
Slide 9: Telemedicine and Home Delivery Fulfillments at New All-Time High
Source: Partner provided fulfillment reports Note: Digital and Print Ads are still active after 2nd week of May Fall Campaign started 9/10 Telemedicine and Home Delivery Fulfillments Achieved a New All-Time High and are 60% Higher Than the Fall Season Average Week Ending Fall TV Campaign Started Con
Slide 10: Launched in 23 OUS countries
Submissions Launches 1Q 18 4Q 17 3Q 17 2Q 17 1Q 17 4Q 16 3Q 16 2Q 16 Saudi Arabia Lebanon UAE Canada Serbia Malta South Africa Saudi Arabia Australia Canada Lebanon UAE Kuwait Greece United Kingdom Ireland Spain Bulgaria Estonia Lithuania Latvia Croatia Slovenia Korea Czech Republic Slovakia Hungary
Slide 11: Evolving Commercial Focus in 2018
Evolving Commercial Focus in 2018
Slide 12: Refinement of Target Audience for Sales Rep Promotion
Refinement of Target Audience for Sales Rep Promotion Effective February 2018 20K HCP Targets Beginning in Aug. 2016, Orexigen targeted 20K HCPs that were responsive to rep promotion 13K (Low ROI) Low volume, low share Fully aware of brand attributes (MOA, efficacy, safety) Willing to prescribe if p
Slide 13: Evolution of Selling Model
Evolution of Selling Model 2018 Model Feb. 2018 Reach and frequency Samples Traditional Speaker Programs New Messaging/Positioning Account Management Focus Business to Business Interactions Direct Accounts Patient Engagement Leverage local thought leaders Digital Speaker Programs Current Model Aug.
Slide 14: Growing Sales with Lower Direct Sales and Marketing Spend
Significantly Growing Sales with a Lower Overall Direct Sales and Marketing Spend $187M $127M Reps: $112M Reps: $77M Reps HCP Mktg. HCP Mktg.: $67M HCP Mktg.: $42M Patient Mktg. Note: 1. Year 1 and 2 base sales expense assume $125 per PDE with 800K and 600K PDEs, respectively with sales training and
Slide 15: 2018 Strategic Objectives
Execute 2018 commercial plan in the United States to continue to drive Contrave prescription and revenue growth Support partners’ advancement of launches and regulatory filings in countries outside the United States Continue positive dialog with regulators regarding completion of post-marketing requ
Slide 16: Backup
Backup
Slide 17: Digital/Social Strategy Rollout
1H 2017 2H 2017 1H 2018 Paid Video & Banner Pinterest Pilot Launch Website Launch Facebook/ Instagram Page Launch Paid Get Contrave Now(GCN) Facebook Digital/Social Strategy Rollout Fall Campaign New CTA Summer Bodies Social Campaign Cross Device Marketing Twitter Pilot Customized Video Site Retarge
Orexigen Therapeutics — Corporate Update (January 2018) on 6ix